Oct 4
|
Eli Lilly's Mounjaro, Zepbound removed from FDA's shortage list
|
Oct 3
|
For Hims & Hers Stock, GLP-1 Giveth and GLP-1 Taketh Away
|
Oct 3
|
Stocks to Watch Thursday: Levi Strauss, Hims & Hers, Constellation Brands, Nvidia
|
Oct 3
|
Hims & Hers stock falls after Eli Lilly's weight-loss drug dropped from shortage list
|
Jul 31
|
Hims & Hers Health Stock Flashing Buy Signal Before Earnings
|
Jun 27
|
Heard on the Street Wednesday Recap: Land of the Rising Sum
|
Jun 26
|
The War Over Cheaper Ozempic Won’t End Well for Some Investors
|
Jun 13
|
Explore These 3 US Growth Companies With High Insider Ownership
|
May 20
|
Investors await Nvidia earnings, commodities on the rise: Morning Brief
|
May 20
|
Heard on the Street: Hims Is Jumping on a Crowded Ozempic Bandwagon
|
May 20
|
Hims & Hers Health to Offer Injectable Weight-Loss Drugs on Telehealth Platform
|
May 20
|
Weight loss: Hims & Hers introduce access to GLP-1 injections
|
May 20
|
Hims & Hers Announces Access to GLP-1 Injections, Passing Cost Savings Onto Customers
|
May 16
|
Hims & Hers Welcomes Anja Manuel, Foreign Policy Expert, Domestic Regulations Advisor, and Former Diplomat to its Board of Directors
|
May 15
|
High Insider Ownership Growth Stocks On US Exchange For May 2024
|
May 9
|
Results: Hims & Hers Health, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
|
May 7
|
Oscar Health, Kenvue, Hims & Hers: Health earnings roundup
|
May 7
|
Telehealth Stock Gains Popularity With Options Bulls
|
May 6
|
Him & Hers Health stock soars on Q1 revenue beat, Q2 guidance
|
May 6
|
Hims & Hers Health, Inc. Reports First Quarter 2024 Financial Results
|